FAS-L (A19) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-FAS-L (A19) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | FAS-L (A19) |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | mouse, rat, human |
| Isotype | n/a |
| Format | unconjugated |
| Size | 0.2 mg |
| Concentration | 0.200 mg/ml |
| Applications | Western Blot (WB), Immunohistochemistry (IHC) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: Mouse, rat and human FAS-L. FAS/APO-1 (CD95) is an important member of the tumor necrosis factor (TNF) superfamily involved in membrane-mediated apoptosis. Ligation of Fas by FAS ligand or an anti-FAS cross-linking antibody, triggers activation of the caspase cascade (1). Functional impairment of the FAS/FAS-L system is associated with the development and progression of malignancies (2). FAS gene mutations have been suggested to have a role in testicular germ cell tumors (3). Tumor cells frequently exhibit de novo expression of FAS-ligand (FAS-L), which plays a significant role in local tissue destruction, metastatic spread, and immune escape of the tumor cells (8). The apoptosis of lymphocytes, which occurs in autoimmune disea |
| Immunogen | Immunogen: Synthetic peptide mapping near the amino terminal domain of rat FAS-L. |
| Other Names | [Fasl protein; Tumor necrosis factor ligand superfamily member 6; tumor necrosis factor ligand superfamily member 6; CD95 ligand; Fas antigen ligand; generalized lymphoproliferative disease; Fas ligand (TNF superfamily, member 6); CD95 ligand; CD95-L], [Fasl; Faslg; gld; CD178; CD95L; Fas-L; Faslg; CD95-L; Tnfsf6; APT1LG1; Apt1lg1; Cd95l; Fasl; gld; Tnfsf6; CD95-L; Fas ligand; FasL; sFasL; APL; FasL ICD; SPA] |
| Gene, Accession # | [FAS-L], Gene ID: 14103, NCBI: AAH52866.1, UniProt: P41047 |
| Catalog # | MBS440039 |
| Price | $240 |
| Order / More Info | FAS-L (A19) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Lin P, Bush JA, Cheung KJ Jr, Li G. Tissue-specific regulation of Fas/APO-1/CD95 expression by p53. Int J Oncol 2002 Aug;21(2):261-4.2. Redondo P, Solano T, VAzquez B, Bauza A, Idoate M. Fas and Fas ligand: expression and soluble circulating levels in cutaneous malignant melanoma. Br J Dermatol 2002 Jul;147(1):80-63. Takayama H, Takakuwa T, Tsujimoto Y, Tani Y, Nonomura N, Okuyama A, Nagata S, Aozasa K. Frequent fas gene mutations in testicular germ cell tumors. Am J Pathology 2002 Aug; 161(2):635-41.4. Hasumi K, Tanaka K, Saitoh S, Takagi A, Miwa T, Mine T, Koga Y. Roles of tumor necrosis factor-alpha-receptor type 1 and Fas in the Helicobacter pylori-induced apoptosis of gastric epithelial cells. J Gastroenterol Hepatol 2002 Jun;17(6):651-658.5. Yukawa M, Iizuka M, Horie Y, Yoneyama K, Shirasaka T, Itou H, Komatsu M, Fukushima T, Watanabe S.Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. Int J Colorectal Dis 2002 Mar;17(2):70-66. Okura T, Watanabe S, Jiang Y, Nakamura M, Takata Y, Yang ZH, Kohara K, Kitami Y, Hiwada K. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 2002 May;20(5):895-87. Hara H, Sato R, Ban Y. Accelerated production of nucleosome in cultured human mononuclear cells in untreated Graves' disease. Endocr J 2002 Apr;49(2):189-948. Reichmann E.The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 2002 Aug;12(4):309-15 |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies